Not yet recruitingNCT07872332Updated Oct 13, 2026

FDG PET/CT Radiomics for True Oligometastatic Breast Cancer

An observational study in Oligometastatic Breast Carcinoma and Radiomics, sponsored by Sohag University. Not yet recruiting. Open to female participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Sohag University · Observational

Updated Oct 13, 2026Newly registeredGo to Updates ↓

Study type: Observational
Model: Cohort
Time perspective: Other
Enrollment: 100
Ages: 18 Years to 90 Years
Sex: Female

Study summary

FDG PET CT Radiomics for True Oligometastatic Breast Cancer

Conditions studied

Oligometastatic Breast Carcinoma
Radiomics

In context

Lead sponsor

Sohag University is the lead sponsor of 1,218 studies on the registry; 627 are open to participants now.

Browse Sohag University studies →

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 90 Years
Sexes eligible: Female
Accepts healthy volunteers: No
Sampling method: Probability sample

Study population

True Oligometastatic Disease Group

Patients fulfilling both criteria:

Presence of ≤5 metastatic lesions at diagnosis.
Persistence of oligometastatic status for at least 24 months without progression to widespread metastatic disease.

Pseudo-Oligometastatic Disease Group

Patients fulfilling both criteria:

Presence of ≤5 metastatic lesions at diagnosis.
Progression to >5 metastatic lesions or development of widespread metastatic disease within 24 months of follow-up.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Female patients aged ≥18 years.
  - Histopathologically confirmed breast carcinoma.
  - Baseline whole-body \^18F-FDG PET/CT available before initiation of systemic treatment for metastatic disease.
  - Presence of oligometastatic disease defined as 1-5 metastatic lesions on baseline imaging.

Exclusion criteria

Exclusion Criteria:

- More than five metastatic lesions at baseline.
  - Previous history of another primary malignancy.
  - Poor image quality unsuitable for radiomic analysis.
  - Incomplete clinical follow-up records.
  - Pregnant patients.

Study design

Observational model: Cohort
Time perspective: Other
Enrollment: 100 participants (estimated)
Target follow-up: 2 Years
Patient registry: Yes

What researchers measure

Primary outcomes

Differentiate true oligometastatic from pseudo oligometastatic breast cancer
Time frame: 1-2 years
Predictive value of conventional PET/CT metabolic parameters (SUVmax, SUVmean, MTV, and TLG) together with radiomic features
Time frame: 1-2 years

Study locations

No study locations are listed for this record.

Timeline

1 registry update since Sep 25, 2026

ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Jun 2027, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered: Sep 30, 2026
First posted: Oct 13, 2026
StartEst.: Oct 1, 2026
Primary completionEst.: Jun 1, 2027
CompletionEst.: Oct 1, 2027
Last update: Oct 13, 2026

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

Registered

First appeared on the registry. No changes since

Oct 13, 2026

Show all 1 update

Oct 13, 2026
First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT07872332
Lead sponsor: Sohag University
Responsible party: Shrouk Atef Abdelsalam (Principal investigator, Sohag University) — Principal investigator
First posted: Oct 13, 2026
Start date: Oct 1, 2026 (estimated)
Primary completion: Jun 1, 2027 (estimated)
Completion: Oct 1, 2027 (estimated)
Last update: Oct 13, 2026

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Sohag University →

Start the discussion